Global Virus Filtration Market
Global virus filtration market will reach $6,275.3 million by 2026, growing by 12.26% annually ov ... Read More
1 Introduction 7 1.1 Industry Definition and Research Scope 7 1.1.1 Industry Definition 7 1.1.2 Research Scope 8 1.2 Research Methodology 11 1.2.1 Overview of Market Research Methodology 11 1.2.2 Market Assumption 12 1.2.3 Secondary Data 12 1.2.4 Primary Data 12 1.2.5 Data Filtration and Model Design 13 1.2.6 Market Size/Share Estimation 14 1.2.7 Research Limitations 15 1.3 Executive Summary 16 2 Market Overview and Dynamics 19 2.1 Market Size and Forecast 19 2.1.1 Impact of COVID-19 on World Economy 21 2.1.2 Impact of COVID-19 on the Market 23 2.2 Major Growth Drivers 25 2.3 Market Restraints and Challenges 28 2.4 Emerging Opportunities and Market Trends 31 2.5 Porter’s Fiver Forces Analysis 35 3 Segmentation of Asia Pacific Market by Vaccine Type 39 3.1 Market Overview by Vaccine Type 39 3.2 Live/Attenuated Vaccines 41 3.3 Inactivated Vaccines 42 3.4 Subunit Vaccines 43 3.5 Toxoid Vaccines 44 3.6 Conjugate Vaccines 45 3.7 Recombinant Vector Vaccines 46 3.8 Other Vaccines 47 4 Segmentation of Asia Pacific Market by Disease 48 4.1 Market Overview by Disease 48 4.2 Vaccines for Pneumococcal Disease 50 4.3 Vaccines for Poliovirus 51 4.4 Vaccines for Hepatitis 52 4.5 Vaccines for Influenza 53 4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 54 4.7 Vaccines for Varicella 55 4.8 Vaccines for Human Papilloma Virus 56 4.9 Vaccines for COVID-19 57 4.10 Vaccines for Other Diseases 60 5 Segmentation of Asia Pacific Market by Administration 61 5.1 Market Overview by Administration 61 5.2 Intramuscular Route 63 5.3 Subcutaneous Route 64 5.4 Oral Route 65 5.5 Intravenous Injection 66 5.6 Other Administration Routes 67 6 Segmentation of Asia Pacific Market by Patient 68 6.1 Market Overview by Patient 68 6.2 Pediatric Vaccines 70 6.3 Adult Vaccines 72 7 Asia-Pacific Market 2020-2026 by Country 74 7.1 Overview of Asia-Pacific Market 74 7.2 China 77 7.3 Japan 80 7.4 India 84 7.5 Australia 87 7.6 South Korea 90 7.7 Rest of APAC Region 93 8 Competitive Landscape 95 8.1 Overview of Key Vendors 95 8.2 New Product Launch, Partnership, Investment, and M&A 98 8.3 Company Profiles 99 AstraZeneca plc 99 Bavarian Nordic A/S 102 China National Biotec Group Company Ltd. 105 CSL Ltd. 107 Daiichi Sankyo Co. Ltd 109 Emergent BioSolutions Inc. 111 GlaxoSmithKline plc 113 Johnson & Johnson 117 Merck & Co. 119 Moderna Inc. 121 Novavax, Inc. 122 Pfizer Inc. 124 Sanofi SA 128 Takeda Pharmaceutical Co. Ltd. 130 9 Investing in Asia Pacific Market: Risk Assessment and Management 132 9.1 Risk Evaluation of Asia Pacific Market 132 9.2 Critical Success Factors (CSFs) 135 Related Reports and Products 138
Table 1. Snapshot of Asia Pacific Preventive Vaccines Market in Balanced Perspective, 2020-2026 17 Table 2. Growth Rate of World GDP, 2020-2022 22 Table 3. Main Product Trends and Market Opportunities in Asia Pacific Preventive Vaccines Market 31 Table 4. Asia Pacific Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 39 Table 5. Asia Pacific Preventive Vaccines Market by Disease, 2016-2026, $ mn 48 Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021 58 Table 7. Asia Pacific Preventive Vaccines Market by Administration, 2016-2026, $ mn 61 Table 8. Asia Pacific Preventive Vaccines Market by Patient, 2016-2026, $ mn 68 Table 9. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 71 Table 10. Asia Pacific Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 73 Table 11. APAC Preventive Vaccines Market by Country, 2016-2026, $ mn 75 Table 12. China Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 78 Table 13. China Preventive Vaccines Market by Disease, 2016-2026, $ mn 78 Table 14. China Preventive Vaccines Market by Administration, 2016-2026, $ mn 79 Table 15. Japan Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 82 Table 16. Japan Preventive Vaccines Market by Disease, 2016-2026, $ mn 82 Table 17. Japan Preventive Vaccines Market by Administration, 2016-2026, $ mn 83 Table 18. India Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 85 Table 19. India Preventive Vaccines Market by Disease, 2016-2026, $ mn 85 Table 20. India Preventive Vaccines Market by C Administration, 2016-2026, $ mn 86 Table 21. Australia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 88 Table 22. Australia Preventive Vaccines Market by Disease, 2016-2026, $ mn 88 Table 23. Australia Preventive Vaccines Market by Administration, 2016-2026, $ mn 89 Table 24. South Korea Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 91 Table 25. South Korea Preventive Vaccines Market by Disease, 2016-2026, $ mn 91 Table 26. South Korea Preventive Vaccines Market by Administration, 2016-2026, $ mn 92 Table 27. Preventive Vaccines Market in Rest of APAC by Country, 2016-2026, $ mn 94 Table 28. AstraZeneca plc: Company Snapshot 99 Table 29. AstraZeneca plc: Revenue, 2018-2020, $ bn 100 Table 30. Bavarian Nordic A/S: Company Snapshot 102 Table 31. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 103 Table 32. China National Biotec Group Company Ltd.: Company Snapshot 105 Table 33. CSL Ltd.: Company Snapshot 107 Table 34. Daiichi Sankyo Co. Ltd.: Company Snapshot 109 Table 35. Emergent BioSolutions Inc.: Company Snapshot 111 Table 36. GlaxoSmithKline: Company Snapshot 113 Table 37. GlaxoSmithKline: Business Segmentation 114 Table 38. GlaxoSmithKline: Product Portfolio 115 Table 39. GlaxoSmithKline: Revenue, 2018-2020, $ bn 116 Table 40. GlaxoSmithKline: Recent Developments 116 Table 41. Johnson & Johnson: Company Snapshot 117 Table 42. Johnson & Johnson: Business Segments 118 Table 43. Merck & Co., Inc.: Company Snapshot 119 Table 44. Merck & Co., Inc.: Business Segmentation 119 Table 45. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 120 Table 46. Moderna Inc.: Company Snapshot 121 Table 47. Novavax, Inc.: Company Snapshot 122 Table 48. Pfizer Inc.: Company Snapshot 124 Table 49. Pfizer Inc.: Business Segmentation 125 Table 50. Pfizer Inc.: Product Portfolio 126 Table 51. Pfizer Inc.: Revenue, 2018-2020, $ bn 127 Table 52. Pfizer Inc.: Recent Developments 127 Table 53. Sanofi: Company Snapshot 128 Table 54. Sanofi: Business Segmentation 128 Table 55. Sanofi: Revenue, 2018-2020, $ bn 129 Table 56. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 130 Table 57. Risk Evaluation for Investing in Asia Pacific Market, 2020-2026 133 Table 58. Critical Success Factors and Key Takeaways 136
Figure 1. Research Method Flow Chart 11 Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14 Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026 16 Figure 4. Asia Pacific Preventive Vaccines Market, 2016-2026, $ mn 19 Figure 5. Development Stages of Preventive Vaccines 20 Figure 6. Impact of COVID-19 on Business 23 Figure 7. Primary Drivers and Impact Factors of Asia Pacific Preventive Vaccines Market 25 Figure 8. Primary Restraints and Impact Factors of Asia Pacific Preventive Vaccines Market 28 Figure 9. Investment Opportunity Analysis 32 Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Preventive Vaccines Market 35 Figure 11. Breakdown of Asia Pacific Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue 40 Figure 12. Contribution to Asia Pacific 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 40 Figure 13. Asia Pacific Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 41 Figure 14. Asia Pacific Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 42 Figure 15. Asia Pacific Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 43 Figure 16. Asia Pacific Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 44 Figure 17. Asia Pacific Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 45 Figure 18. Asia Pacific Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 46 Figure 19. Asia Pacific Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 47 Figure 20. Breakdown of Asia Pacific Preventive Vaccines Market by Disease, 2020-2026, % of Revenue 49 Figure 21. Contribution to Asia Pacific 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 49 Figure 22. Asia Pacific Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 50 Figure 23. Asia Pacific Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 51 Figure 24. Asia Pacific Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 52 Figure 25. Asia Pacific Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 53 Figure 26. Asia Pacific Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 54 Figure 27. Asia Pacific Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 55 Figure 28. Asia Pacific Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 56 Figure 29. Asia Pacific Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 57 Figure 30. Asia Pacific Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 60 Figure 31. Breakdown of Asia Pacific Preventive Vaccines Market by Administration, 2020-2026, % of Revenue 62 Figure 32. Contribution to Asia Pacific 2021-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 62 Figure 33. Asia Pacific Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 63 Figure 34. Asia Pacific Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 64 Figure 35. Asia Pacific Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 65 Figure 36. Asia Pacific Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 66 Figure 37. Asia Pacific Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 67 Figure 38. Breakdown of Asia Pacific Preventive Vaccines Market by Patient, 2020-2026, % of Revenue 68 Figure 39. Contribution to Asia Pacific 2021-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 69 Figure 40. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 70 Figure 41. Asia Pacific Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 72 Figure 42. Breakdown of APAC Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 75 Figure 43. Contribution to APAC 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 76 Figure 44. Preventive Vaccines Market in China, 2016-2026, $ mn 77 Figure 45. Preventive Vaccines Market in Japan, 2016-2026, $ mn 81 Figure 46. Preventive Vaccines Market in India, 2016-2026, $ mn 84 Figure 47. Preventive Vaccines Market in Australia, 2016-2026, $ mn 87 Figure 48. Preventive Vaccines Market in South Korea, 2016-2026, $ mn 90 Figure 49. Preventive Vaccines Market in Rest of APAC, 2016-2026, $ mn 93 Figure 50. Growth Stage of Asia Pacific Preventive Vaccines Industry over the Forecast Period 95 Figure 51. Top Products of AstraZeneca Based on Revenue from 2016 to 2019 (in million U.S. dollars) 100
Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca plc Bavarian Nordic A/S China National Biotec Group Company Ltd. CSL Ltd. Daiichi Sankyo Co. Ltd Emergent BioSolutions Inc. GlaxoSmithKline plc Johnson & Johnson Merck & Co. Moderna Inc. Novavax, Inc. Pfizer Inc. Sanofi SA Takeda Pharmaceutical Co. Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Global virus filtration market will reach $6,275.3 million by 2026, growing by 12.26% annually ov ... Read More
North America virus filtration market is expected to grow by 11.86% annually in the forecast peri ... Read More
Europe virus filtration market accounted for $696.7 million in 2019 and will grow by 11.34% annua ... Read More
Asia Pacific virus filtration market will grow by 14.72% annually with a total addressable market ... Read More